Loading...
Concert Pharmaceuticals, Inc.
CNCE•NASDAQ
HealthcareBiotechnology
$8.37
$0.00(0.00%)
Concert Pharmaceuticals, Inc. (CNCE) Stock Overview
Explore Concert Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for CNCEStats details for CNCE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CNCEAnalyst Recommendations details for CNCE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
CEO
Dr. Roger D. Tung Ph.D.
Employees
64
Headquarters
65 Hayden Avenue, Lexington, MA
Founded
2014